Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution